Item 5. Other Information
Item 5. Other Information.
Rule 10b5-1 Trading Plans
During the quarter ended June 30, 2025, none of our directors or executive officers adopted, modified or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement” (as defined in Item 408 of Regulation S-K).
Item 6. Exhibits.
10.1
Credit Agreement, dated July 31 , 2025, among Myriad Genetics, Inc. , the lenders from time t o time party thereto, and Orbimed Royalty and Credit Opportunities IV, LP, as initial lender and administrative agent (incorporated by reference to E xhibit 10.1 to the Com pany's Current Report on Form 8-K, File No . 000-26642 , filed with the SEC on July 31 , 2025 ) .
10.2
Ple dge and Secu rity Agreement, dated July 31 , 2025, among Myriad Genetics, Inc., each of the other Guarantors and Orbimed Royalty and Credit Opportunities IV, LP, as administrative agent for the secured p arties ( incorporated by reference to Exhibit 10. 2 to the Company's Current Report on Form 8-K, File No. 000-26642 , filed with the SEC on July 31 , 2025 ) .
10.3+
2017 Employee, Director and Consultant Equity Incentive Plan, as amended ( incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K, File No. 000-26642 , filed with the SEC on June 5, 2025 ) .
10.4+
Non-Employee Director Compensation Policy.
10.5+
Restricted Stock Unit Agreement, dated May 1, 2025, by and between the Company and Brian Donnelly (incorporated by reference to Exhibit 10.9 to the Company's Quarterly Report on Form 10-Q, File No. 000-26642, filed with the SEC on May 7, 2025 ).
10.6+
Perf o r mance-Based Restricted Stock Unit Agreement, dated May 1, 2025, by and between the Company and Brian Donnelly (incorporated by reference to Exhibit 10. 10 to the Company's Quarterly Report on Form 10-Q, File No. 000-26642, filed with the SEC on May 7, 2025).
31.1 Certification of Chief Executive Officer pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002.
31.2 Certification of Chief Financial Officer pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002.
32.1 Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Furnished).
101.INS Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH Inline XBRL Taxonomy Extension Schema Document.
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104 The cover page from the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 has been formatted in Inline XBRL.
+ Management contract or compensatory plan or arrangement.
35
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
MYRIAD GENETICS, INC.
Date: August 6, 2025 By: /s/ Samraat S. Raha
Samraat S. Raha
President and Chief Executive Officer
(Principal executive officer)
Date: August 6, 2025 By: /s/ Scott J. Leffler
Scott J. Leffler
Chief Financial Officer
(Principal financial officer)
Date: August 6, 2025 By: /s/ Natalie Munk
Natalie Munk
Chief Accounting Officer
(Principal accounting officer)
36
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.